Top Markets
#1 B3 (Base) B3 (Base) +17.71%
#2 Siacoin Siacoin +14.92%
#3 BORA BORA +4.81%
#4 The Black Bull The Black Bull +4.53%
#5 MVL MVL +4.32%
#6 TROLL TROLL +4.30%
#7 Kaia Kaia +4.24%
#8 OriginTrail OriginTrail +3.41%
#9 Stratis Stratis +3.39%
#10 Power Ledger Power Ledger +3.13%
Coin of the day
B3 (Base) B3 (Base)
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Energenesis Biomedical CO.,LTD. Energenesis Biomedical CO.,LTD.

Energenesis Biomedical CO.,LTD.

6657
Peringkat dalam Saham #22642
Energenesis Biomedical CO.,LTD., a firm established in 2012 and headquartered... Energenesis Biomedical CO.,LTD., a firm established in 2012 and headquartered in Taipei, Taiwan, is an active participant in the biomedicine sector. The company specializes in the development of a diverse range of medical solutions and research materials. Its primary pharmaceutical pipeline includes ENERGI-F703, which is currently undergoing Phase II clinical trials for the treatment of diabetic foot ulcers, and ENERGI-F701, a topical solution for addressing alopecia that is also in its second phase of clinical assessment. The comprehensive portfolio of therapeutic agents further encompasses: ENERGI-F711, formulated as a cream for burns. ENERGI-F702, designed to combat metabolic diseases. ENERGI-F704, targeting inflammatory bowel disease. ENERGI-F708, for the management of asthma. ENERGI-F705, aimed at controlling Parkinson's disease. ENERGI-F707, addressing mitochondrial deficiencies. ENERGI-F706, used to treat cachexia. ENERGI-F709, which serves as a vaccine adjuvant. ENERGI-F710, intended for the regulation of blood phosphate levels. Beyond its therapeutic developments, Energenesis Biomedical also provides a selection of scientific research products, including reagents for Western blotting, cell culture supplements, components for protein isolation and quantification, various laboratory dyes, and buffer solutions.
Harga Saham
$0.97305026
Terakhir disinkronkan: 2026-08-21
Kapitalisasi Pasar
$85.54M
Perubahan (1 hari)
1.16%
Perubahan (1 tahun)
-50.40%
Negara
TW
Perdagangan Energenesis Biomedical CO.,LTD. (6657)

Kategori

Healthcare
Rasio P/E untuk Energenesis Biomedical CO.,LTD. (6657)
Rasio P/E per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Energenesis Biomedical CO.,LTD., rasio P/E saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki rasio P/E sebesar 0.
Riwayat rasio P/E untuk Energenesis Biomedical CO.,LTD. dari 2026 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.